{
    "Trade/Device Name(s)": [
        "MammaPrint FFPE NGS kit"
    ],
    "Submitter Information": "Agendia Inc.",
    "510(k) Number": "K210973",
    "Predicate Device Reference 510(k) Number(s)": [
        "K201902",
        "K141142"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "March 31, 2021",
    "Summary Letter Received Date": "March 31, 2021",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene Expression Profiling Test System For Breast Cancer Prognosis"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "MammaPrint 70-gene Breast Cancer signature"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Next Generation Sequencing (NGS) platform"
    ],
    "Method(s)/Technology(ies)": [
        "Target enrichment",
        "Next Generation Sequencing (NGS)",
        "RNA isolation",
        "cDNA library preparation",
        "Gene expression analysis"
    ],
    "Methodologies": [
        "Gene expression profiling"
    ],
    "Submission Type(s)": [
        "Kit",
        "Assay",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for MammaPrint FFPE NGS kit using NGS-based gene expression profiling to assess breast cancer recurrence risk",
    "Indications for Use Summary": "Qualitative in vitro diagnostic kit for gene expression profiling of the 70-gene MammaPrint breast cancer signature on FFPE tissue, assessing patient risk of distant metastasis within 5 and up to 10 years after diagnosis in Stage I or II, \u22645.0 cm, lymph node negative breast cancer, to be used as a prognostic marker with other clinicopathological factors",
    "fda_folder": "Immunology"
}